Vor Bio Doses First Participant In UPSTREAM SjD Phase 3 Study Of Telitacicept In Adult Patiens With Sjögren's Disease

Vor Bio (Nasdaq: VOR) has commenced the UPSTREAM SjD Phase 3 trial by dosing the first participant. This global, randomized, double-blind, placebo-controlled study aims to evaluate the efficacy of telitacicept in treating adult patients with active primary Sjögren's disease.